Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neuroblastoma 2Glioblastoma 2Recurrence 1Melanoma 1Medulloblastoma 1Gliosarcoma 1Disease Progression 1Central Nervous System Neoplasms 1Brain Neoplasms 1

Interventions

Temozolomide 14Radiotherapy 14Carboplatin 7Irinotecan 6Everolimus 5Filgrastim 4Carmustine 4Surgical Procedures, Operative 3Radiation 3Paclitaxel 3Ifosfamide 3selpercatinib 2pembrolizumab 2Trastuzumab 2Peripheral Blood Stem Cell Transplantation 2Nivolumab 2Methotrexate 2Imatinib Mesylate 2IL13-PE38 2Dasatinib 2Chemotherapy, Adjuvant 2Bevacizumab 2vitespin 1veliparib 1vatalanib 1transforming growth factor(alpha)-Pseudomonas aeruginosa exotoxin (38) 1tipifarnib 1terameprocol 1temsirolimus 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Central Nervous System Neoplasms × TPI-287 × Clear all
NCT01582152 2019-06-05

Phase I/II Bevacizumab Versus Bevacizumab Plus TPI 287 for Recurrent Glioblastoma

M.D. Anderson Cancer Center

Phase 1/2 Terminated
12 enrolled 7 charts
CNSSarcoma

Brain Neoplasms, Glioblastoma, Central Nervous System Neoplasms, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡